Efficacy of Low‐Dose Naltrexone in Women With Fibromyalgia Syndrome: A 12‐Month Randomised, Double‐Blind, Placebo‐Controlled Single‐Centre Clinical Trial ( INNOVA Study)
European Journal of Pain · 2026
DOI: 10.1002/ejp.70321 ↗At a glance
Randomisierte kontrollierte Studie in European Journal of Pain, 2026. Written by Carla Rodríguez-Freire and 7 co-authors. Institution: Teaching, Research & Innovation Unit, Parc Sanitari Sant Joan de Déu, Sant Boi de Llobregat, Spain. Major MEDLINE topics: Fibromyalgia, Naltrexone, Narcotic Antagonists. Cited 2 times so far (Crossref); 45 references. The full text is freely available (open access, CC BY-NC-ND 4.0).
Abstract (original language)
Background
Low‐dose naltrexone (LDN) has been used off‐label for fibromyalgia syndrome (FMS) for over a decade, supported by small crossover trials. The INNOVA study evaluated the safety and efficacy of LDN 4.5 mg versus placebo on pain intensity over 12 months in women with FMS.
Methods
In total, 98 women with FMS were randomised to LDN 4.5 mg/day ( n = 48) or placebo ( n = 50). The primary outcome was change in pain intensity (NRS 0–10) from baseline to 3 months in the intention‐to‐treat population. Secondary outcomes included functional impairment (FIQR), anxiety‐depressive symptoms (DASS‐21), cognitive impairment (MISCI), disability (WHODAS 2.0), pathological worry (GAD‐7) and impression of change (PGIC/PSIC), assessed at baseline and at 3, 6 and 12 months. Perceived treatment allocation and safety were also assessed.
Results
At 3 months, mean change in pain intensity was −0.33 points with LDN and −0.64 with placebo, with an adjusted between‐group difference of 0.49 ( p = 0.236, d = 0.19). Secondary outcomes showed minor and inconsistent changes, with low and similar responder rates ( p = 0.219–0.954). Exploratory analyses suggested some improvement among participants who believed they had received LDN, although effects were inconsistent. Adverse events, predominantly mild and transient, were reported by 33 (68.8%) participants in LDN and 36 (72%) in placebo, and no treatment‐related serious events occurred.
Conclusions
LDN was well tolerated but did not demonstrate a clinically meaningful benefit over placebo for pain‐related outcomes, underscoring the need for more effective pharmacological treatments. Significance Statement This RCT provides the first long‐term evidence on the efficacy and safety of LDN in FMS. LDN (4.5 mg), administered as an add‐on treatment, has a favourable safety profile, but the findings indicate that it does not produce clinically meaningful improvements in FMS symptoms compared to placebo at short‐ or long‐term follow‐up. These findings contribute to the growing body of evidence questioning its clinical utility.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Teaching, Research & Innovation Unit, Parc Sanitari Sant Joan de Déu, Sant Boi de Llobregat, Spain.
- Centre for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.
- Department of Rheumatology, Parc Sanitari Sant Joan de Déu, Sant Boi de Llobregat, Spain.
- Unit for the Study and Treatment of Pain-ALGOS, Department of Psychology, Research Center for Behavior Assessment (CRAMC), Universitat Rovira i Virgili, Tarragona, Spain.
- Institut d'Investigació Sanitària Pere Virgili, Universitat Rovira i Virgili, Tarragona, Spain.
- Department of Pharmacy, Parc Sanitari Sant Joan de Déu, Sant Boi de Llobregat, Spain.
ORCID profiles: Carla Rodríguez-Freire, Jaime Navarrete, Antoni Rozadilla-Sacanell, Juan P Sanabria-Mazo, Xavier Borràs, Albert Feliu-Soler, Juan V Luciano
Cite
APA
Rodríguez-Freire, C., Navarrete, J., Rozadilla-Sacanell, A., Sanabria-Mazo, J. P., Del Pino-Gaya, B., Borràs, X., Feliu-Soler, A., & Luciano, J. V. (2026). Efficacy of Low‐Dose Naltrexone in Women With Fibromyalgia Syndrome: A 12‐Month Randomised, Double‐Blind, Placebo‐Controlled Single‐Centre Clinical Trial ( INNOVA Study). European Journal of Pain. https://doi.org/10.1002/ejp.70321
Vancouver
Rodríguez-Freire C, Navarrete J, Rozadilla-Sacanell A, Sanabria-Mazo JP, Del Pino-Gaya B, Borràs X, et al. Efficacy of Low‐Dose Naltrexone in Women With Fibromyalgia Syndrome: A 12‐Month Randomised, Double‐Blind, Placebo‐Controlled Single‐Centre Clinical Trial ( INNOVA Study). European Journal of Pain. 2026. doi:10.1002/ejp.70321
BibTeX
@article{RodrguezFreire2026,
author = {Rodríguez-Freire, Carla and Navarrete, Jaime and Rozadilla-Sacanell, Antoni and Sanabria-Mazo, Juan P and Del Pino-Gaya, Beatriz and Borràs, Xavier and Feliu-Soler, Albert and Luciano, Juan V},
title = {Efficacy of Low‐Dose Naltrexone in Women With Fibromyalgia Syndrome: A 12‐Month Randomised, Double‐Blind, Placebo‐Controlled Single‐Centre Clinical Trial ( INNOVA Study)},
journal = {European Journal of Pain},
year = {2026},
doi = {10.1002/ejp.70321}
}
EUVIMED